Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors
Ana M. García(University of Trieste), Carmen Gil(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Olga Valverde(Universitat Pompeu Fabra), José Á. Morales-García(Universitat de Vic - Universitat Central de Catalunya), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Irene Gracia‐Rubio(Universitat Pompeu Fabra), José Brea(Universidade de Santiago de Compostela), Marı́a Isabel Loza(Universidade de Santiago de Compostela), Clara Ros‐Simó(Universitat Pompeu Fabra), Sandra Alonso‐Gil(Biomedical Research Networking Center on Neurodegenerative Diseases), Alejandro González(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas), Daniel I. Pérez(Cedars-Sinai Medical Center), Santiago Conde(Consejo Superior de Investigaciones Científicas), Marı́a Isabel Cadavid(Universidade de Santiago de Compostela)
Cited by 37
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
|PLoS Pathogens|2016|451
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334